Clinical Trials Logo

Clinical Trial Summary

Molecular profiling of lung cancers using circulating tumor DNA (ctDNA) in the blood of patients is rapidly becoming established as a useful source of information to aid clinical decision-making. This study is aimed to to compare concordance rate between tissue based cancer panel analysis and blood based cancer panel analysis in lung cancer patients (both by NGS technique).


Clinical Trial Description

This study is comprised of two cohorts as below:

Cohort A: inoperable, untreated, non-small cell lung cancer patients

Cohort B: non-small cell lung cancer patients who are in the treatment with targeted agents including immune checkpoint inhibitors ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03235765
Study type Observational [Patient Registry]
Source Seoul National University Hospital
Contact
Status Active, not recruiting
Phase
Start date March 10, 2017
Completion date March 10, 2020

See also
  Status Clinical Trial Phase
Terminated NCT03168464 - Radiation and Immune Checkpoints Blockade in Metastatic NSCLC (BMS # CA209-632) Phase 1/Phase 2
Recruiting NCT05117242 - Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of Recurrent (Non-small Cell) Lung Cancer Phase 2
Completed NCT04470440 - Thyroid Dysfunction and Nivolumab Reponse in NSCLC
Completed NCT03304093 - Immunotherapy by Nivolumab for HIV+ Patients Phase 2
Terminated NCT04069936 - Marrow Infiltrating Lymphocytes - Non-Small Cell Lung Cancer (MILs™ - NSCLC) Alone or in Combination With Nivolumab With or Without Tadalafil in Locally Advanced and Unresectable or Metastatic NSCLC Phase 2
Active, not recruiting NCT03307785 - Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042 Phase 1
Recruiting NCT06100796 - Effect of DM on Outcomes and Response Rate in Patients With Advanced NSCLC on ICI
Recruiting NCT03533127 - A Study of LY01008 and Bevacizumab Combined With Paclitaxel and Carboplatin for Treatment of Naïve Subjects With Metastatic or Recurrent Nonsquamous Non-small Cell Lung Cancer Phase 3
Completed NCT04187768 - Immunological Profile Changes In Patients With Advanced Non-Small Cell Lung Cancer
Active, not recruiting NCT04951583 - Fecal Microbial Transplantation Non-Small Cell Lung Cancer and Melanoma Phase 2
Active, not recruiting NCT03133546 - Osimertinib and Bevacizumab Versus Osimertinib Alone as Second-line Treatment in Stage IIIb-IVb NSCLC With Confirmed EGFRm and T790M (BOOSTER) Phase 2
Completed NCT03845270 - Her2-positive Lung Cancer Treated With Dedicated Drug Phase 2
Recruiting NCT05274451 - A Study to Investigate LYL797 in Adults With Solid Tumors Phase 1
Recruiting NCT03774732 - PD-1 Inhibitor and Chemotherapy With Concurrent Irradiation at Varied Tumour Sites in Advanced Non-small Cell Lung Cancer Phase 3
Recruiting NCT04621188 - Lorlatinib After Failure of First-line TKI in Patients With Advanced ROS1-positive NSCLC (ALBATROS) Phase 2
Not yet recruiting NCT03732482 - Temozolomide Combine With Intensity Modulated Radiation Therapy With Simultaneous Integrated Boost for Non Small Cell Lung Cancer Brain Metastases Phase 2/Phase 3
Active, not recruiting NCT02978404 - Combining Radiosurgery and Nivolumab in the Treatment of Brain Metastases Phase 2
Recruiting NCT05853887 - Liquid Biopsy Based NGS in Newly Diagnosed NSCLC N/A
Recruiting NCT05429320 - A Study of Local Ablative Therapy (LAT) in People With Non-Small Cell Lung Cancer (NSCLC) Phase 2
Active, not recruiting NCT03977194 - Atezolizumab in Elderly Patients With Advanced Non-Small-Cell Lung Cancer and Receiving Carboplatin Paclitaxel Chemotherapy Phase 3